In clinical studies in dyslipidaemic patients gemfibrozil has produced falls in LDL and VLDL of 10-20% and 30-50%, respectively, but a rise in HDL of 15-25%. Gemfibrozil also produces increases in both Apo AI and AII, and in kininogen and prekallikrein. Side-effects are not a major problem. The Helsinki Heart Study has compared the effects of gemfibrozil with those of placebo in a group of 4080 dyslipidaemic Finnish men aged 40-55. The results are not yet available but there is reason to believe that the probable level of coronary risk reduction will be at least as great as that reported by the Lipid Research Clinics Study Coronary Primary Prevention Trial (LRC-CPPT).
在对血脂异常患者的临床研究中，吉非贝齐使低密度脂蛋白（LDL）和极低密度脂蛋白（VLDL）分别下降了10% - 20%和30% - 50%，但使高密度脂蛋白（HDL）升高了15% - 25%。吉非贝齐还使载脂蛋白AI和AII、激肽原和前激肽释放酶增加。副作用不是主要问题。赫尔辛基心脏研究比较了吉非贝齐与安慰剂对一组4080名年龄在40 - 55岁的血脂异常芬兰男性的影响。结果尚未公布，但有理由相信，降低冠心病风险的可能程度至少与脂质研究临床中心冠心病一级预防试验（LRC - CPPT）报告的程度一样大。
Zotero 插件